The Owl-Eyed, Herculean Cancroid- Hodgkin’s Lymphoma

Abstract

Initially scripted by Dr Thomas Hodgkin (1798-1866) in 1832, Hodgkin’s Lymphoma is a neoplasm, essentially
disseminated in a predominantly non-malignant cell population the lymphoma comprises chiefly of T lymphocytes. The
classic Hodgkin’s lymphoma (c HL) and the subtype lymphocyte predominance (NLPHD) commences with a B cell clone.
The age predominance, surmises two definitive developments: i) A minimally infective agent contaminates the young
adults and ii) A synergistic conformity of lymphomas that may explain the pathogenesis of adult Hodgkin’s lymphoma.
The Epstein Barr Virus (EBV) may be implicated in 30%-50% of the immune competent Hodgkin’s lymphomas. Array
based comparative genomic hybridization (a CGH) may be applied to analyze the genes applicable in the pathogenesis of
c HL. The Ann Arbor classification delineates the dominant prognostic categories as the LIMITED (EARLY STAGE) and
ADVANCED DISEASE. The Early Stage includes the stage I and II while stage III and IV are encompassed in the Advanced
Disease. Stage II along with the systemic symptoms (II B) may be incorporated in the subclass of UNFAVOURABLE Early
Stage Disease. The mortality of Hodgkin’s Lymphoma has diminished considerably with the current 5 year survival rate at
81%. Where no therapy has been instituted, the survival extends to 1- 2 years with < 5% of patients existing at 5 years.